The European Patent Office has granted Brighter's patent application.

The European Patent Office has granted Brighter's patent application no. 14864054.3, regarding method and device for logging drug injections made by a medical device with injector.

– Over the years, Brighter has built an strong IP portfolio, and we are continuously strengthening it even further through continuous development within both current and new upcoming business areas. As part of the company's long-term strategy IP is considered an active asset that strengthens existing business but also enables e.g. licensing, says Truls Sjöstedt, Brighter's CEO and founder.

For more information, please contact:

Truls Sjöstedt, CEO      
Telefon: +46 709 73 46 00      
E-post:  truls.sjostedt@brighter.se

Henrik Norström, COO      
Telefon: +46 733 40 30 45      
E-post: henrik.norstrom@brighter.se

About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injection, and automatic logging and timing of all activity are done in a single unit. Actiste is connected via an autonomous and secure mobile connection, the information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed.

Validated user-generated data, such as as test results, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives ' concerns, and release enormous healthcare resources. www.actiste.com

About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of the most serious healthcare problems: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and close associates, healthcare providers, research, pharmaceutical industry and society. www.brighter.se

The Company's shares are listed on NASDAQOMX First North/BRIGBrighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic Holding AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on February 2, 2018.

About Us

Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first innovative tool Actiste®, the company creates a more efficient care chain with focus on the individual. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.

Subscribe

Documents & Links